Devices and methods for modulating ADMA in blood
AssigneeThe Trustees of Indiana University
InventorJaipal Singh
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for metabolically degrading ADMA. In one embodiment a device is provided for reducing a patients ADMA levels in their blood wherein the device comprises a biologically active dimethylarginine dimethylaminohydrolase (DDAH) polypeptide covalently linked to a solid support. In one embodiment a method for reducing ADMA levels in a patients blood comprises the step of contacting the patients blood or a blood fraction with an immobilized biologically active DDAH polypeptide, wherein contact of the patients blood with said DDAH polypeptide results in degradation of ADMA present in the patients blood.
Claims8
An ex vivo method for reducing ADMA in patients on dialysis, in ICU and disease states including kidney disease, acute kidney injury, sepsis, lung injury, preeclampsia, said method comprising the step of
- contacting the patient's blood or plasma with a biologically active DDAH polypeptide covalently linked to a solid support of a therapeutic extracorporeal medical device, wherein the biologically active DDAH polypeptide comprises SEQ ID NO:13, wherein contact of the patient's blood or plasma with said DDAH polypeptide results in degradation of ADMA present in the patient's blood or plasma;
- and
- returning the contacted blood or plasma to the circulation of the patient.
Dependencies are inferred from the claim text.